Premium
Use of the cell division assay to diagnose Fanconi anemia patients' hypersensitivity to mitomycin C
Author(s) -
Hammarsten Ola,
Muslimovic Aida,
Thunström Sofia,
Ek Torben,
Johansson Pegah
Publication year - 2021
Publication title -
cytometry part b: clinical cytometry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.646
H-Index - 61
eISSN - 1552-4957
pISSN - 1552-4949
DOI - 10.1002/cyto.b.21950
Subject(s) - mitomycin c , fanconi anemia , cytotoxic t cell , peripheral blood mononuclear cell , cyclophosphamide , in vitro , immunology , cytotoxicity , chemistry , pharmacology , microbiology and biotechnology , medicine , biology , chemotherapy , dna repair , dna , biochemistry , surgery
The recently reported cell division assay (CDA) was optimized to measure the relative sensitivity of cells to cytotoxic drugs in vitro. Here, we investigated the in vitro hypersensitivity of lymphocytes from Fanconi anemia (FA) patients, to cytotoxic drugs using CDA. Peripheral blood mononuclear cells (PBMC) as well as cell lines derived from FA patients were treated with two DNA interstrand crosslinking (ICL) agents, mitomycin C and cyclophosphamide. Our data indicate that the CDA detects hypersensitivity of cells from FA patients to mitomycin C. Further, cell lines derived from FA‐patients were also hypersensitive to mitomycin C as well as cyclophosphamide, when assayed by the CDA. This study suggests that the CDA is a useful alternative for the diagnosis of FA patients' hypersensitivity to ICL agents.